BioPharma Credit (LSE: BPCR)

Last close As at 23/05/2024

0.96

0.00 (0.00%)

Market capitalisation

USD1,258m

Latest Insights

View More

Investment Companies | Review

Biopharma Credit — A quality dividend play with FY22 yield of 12%

Investment Companies | edison tv

BioPharma Credit – executive interview

Investment Companies | Update

Biopharma Credit — New transaction of up to US$50m

Investment Companies | Update

Biopharma Credit — Fully invested after recent transactions

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (0.2) (0.6) (3.4)
Relative (4.2) (9.7) (4.8)
52 week high/low US$1.0/US$0.9

Overview

BioPharma Credit (BPCR) is on track to deliver a strong (possibly record-high) annual NAV total return (TR) in FY22 on the back of a high investment level in H122, rising interest rates benefiting its floating rate loans, as well as healthy prepayment and make-whole fees from the early loan repayments in recent months. This has allowed BPCR to announce a US$0.045 special dividend, which implies a 12.0% dividend yield for FY22 on the current share price. The above-mentioned fees also provide BPCR with a good income runway for the re-deployment of prepayment proceeds. Since being fully invested in August 2018, BPCR achieved a net NAV TR of c 8% per year.

Research

Update

Investment Companies

Biopharma Credit — Fully invested after recent transactions

Update

Investment Companies

Biopharma Credit — Now listed in the Premium Segment of LSE

Review

Investment Companies

BioPharma Credit — Debt investment in a COVID-19 test provider

Review

Investment Companies

Biopharma Credit — Reinvesting proceeds from loan prepayments

Review

Investment Companies

Biopharma Credit — Debt investment in Collegium Pharmaceutical

Review

Investment Companies

Biopharma Credit — High investment volume in H219

Review

Investment Companies

Biopharma Credit — Invests in Epizyme and Akebia

edison tv

Investment Companies

Bitesize briefing – BioPharma Credit

Thematics

thematic

Investment Companies

UK stock market – Scope for further upside in UK large-cap stocks

thematic

Investment Companies

Listed private equity – Performing a balancing act

thematic

Investment Companies

European equities

thematic

Investment Companies

Listed Private Equity

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free